Posted by Michael Wonder on 17 Oct 2022
Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss
17 October 2022 - Quebec leads the way as the first province to reimburse Luxturna (voretigene neparvovec) for previously untreatable inherited retinal disease.
Novartis Pharmaceuticals Canada Inc. is pleased to announce Luxturna (voretigene neparvovec) is now available to Quebec patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations under the province's public health plan.
